Drug class
Nectin-4-directed antibody–drug conjugate (ADC); microtubule-disrupting antineoplastic
Mechanism of action
The antibody binds Nectin-4 on tumour cells and is internalised. Intracellular cleavage releases monomethyl auristatin E (MMAE), a microtubule-disrupting agent that inhibits cell division and induces apoptosis.
General use cases
- Treatment of adults with locally advanced or metastatic urothelial cancer in combination with pembrolizumab as first-line therapy under the current US product indication
- Treatment of adults with locally advanced or metastatic urothelial cancer previously treated with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy, where applicable under the product label
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
